Wegovy (semaglutide 2.4 mg) is a prescription-only injectable medication, so ordering it starts with a healthcare provider visit and ends at a pharmacy. The cost and hassle between those two steps vary enormously depending on your insurance. At full list price, Wegovy runs roughly $1,300 to $1,400 per month, but what you actually pay could be anywhere from under $50 to the full retail amount depending on your plan, your employer, and which state you live in. Coverage is expanding but remains inconsistent, and the gap between who could benefit from the drug and who can realistically afford it is one of the more frustrating realities in modern medicine.
Who Qualifies for a Wegovy Prescription
Wegovy is FDA-approved for chronic weight management in adults with a body mass index (BMI) of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as high blood pressure, type 2 diabetes, or high cholesterol. It is also approved for adolescents aged 12 and older who meet similar BMI thresholds. In 2024, the FDA expanded Wegovy’s approved uses to include reducing the risk of major cardiovascular events in adults with established heart disease and overweight or obesity, which has significant implications for insurance coverage discussed below.
You can get a Wegovy prescription through a primary care doctor, an endocrinologist, an obesity medicine specialist, or increasingly through telehealth platforms. Many online weight-management services now offer virtual consultations specifically for GLP-1 medications, where a provider reviews your health history, confirms your eligibility, and sends the prescription electronically to a pharmacy. Whether you go the in-person or virtual route, the prescribing clinician will typically check your medical history for conditions that might rule out semaglutide, including a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2. Expect to have your weight, height, and basic labs reviewed before getting the prescription.
The Dose Titration Schedule
Wegovy is not a drug you start at full strength. The labeled protocol calls for a gradual monthly dose escalation over 16 weeks: you begin at 0.25 mg weekly for the first month, increase to 0.5 mg for the second month, then 1.0 mg, then 1.7 mg, and finally reach the maintenance dose of 2.4 mg weekly by month five. Each dose level comes as a separate pen, so your pharmacy fills a new strength each month during the ramp-up period. This stepwise approach is designed to reduce gastrointestinal side effects like nausea, which tend to be worst during the early weeks and at each dose increase.
In practice, many people deviate from this schedule. A study of commercially insured U.S. adults found that most semaglutide users did not follow the recommended monthly dose escalation within the first five months, and by the fifth month nearly half had discontinued treatment entirely.1Wiley Online Library. Titration and discontinuation of semaglutide for weight management in commercially insured US adults Some people stay on lower doses longer because they cannot tolerate the side effects at higher levels; others stop because of cost or supply issues. Your prescriber can adjust the schedule based on how you respond, and some people achieve meaningful weight loss on doses below the full 2.4 mg maintenance level.
What Wegovy Costs Without Insurance
The manufacturer’s list price for Wegovy is roughly $1,300 to $1,400 per month, depending on the dose and pharmacy. That is the cash price before any insurance, discount programs, or manufacturer coupons. For a medication that is designed as long-term or indefinite therapy, this adds up fast: you are looking at around $16,000 per year at list price.
Novo Nordisk, the company that makes Wegovy, offers a savings card that can reduce out-of-pocket costs for commercially insured patients. Eligibility and the discount amount change over time, so it is worth checking the manufacturer’s website for current terms. Patients without any insurance coverage sometimes turn to patient assistance programs, though these typically have income requirements and may not be available to everyone. Some pharmacies and third-party discount services negotiate lower cash prices, but even discounted prices tend to remain in the hundreds of dollars per month range.
Commercial Insurance Coverage
Whether your employer-sponsored or marketplace health plan covers Wegovy depends on the specific plan, and the variation is enormous. An analysis of the largest U.S. commercial health plans found that coverage for semaglutide for obesity differs widely from plan to plan, meaning access often hinges on which health plan your employer happens to offer rather than on medical need.2Tufts Center for the Evaluation of Value and Risk in Health. How US Commercial Health Plans Cover Semaglutide for Obesity Some plans cover Wegovy with a standard specialty-drug copay, others require prior authorization or documented failure of other weight loss methods first, and some exclude weight management drugs altogether.
Even when a plan technically covers the medication, the copay can be substantial. The study of commercially insured semaglutide users found that discontinuation was strongly tied to how much patients paid out of pocket each month: those with the lowest copays (under about $55 per month) had a discontinuation rate of around 41%, while those paying the most (over $160 per month) saw rates climb to about 51%.1Wiley Online Library. Titration and discontinuation of semaglutide for weight management in commercially insured US adults The practical upshot: before filling a prescription, call your insurer and ask specifically whether Wegovy is on the formulary, what tier it falls under, whether prior authorization is required, and what your estimated copay will be. Getting surprised by a $400 copay at the pharmacy counter is a common and avoidable frustration.
If your plan denies coverage or places Wegovy on a non-preferred tier, you have options. Your prescriber can submit a prior authorization request with clinical documentation, and many plans have an appeals process. Some plans that exclude “weight loss drugs” may still cover Wegovy under its cardiovascular risk-reduction indication if you have established heart disease, since that falls outside the weight management exclusion. This is a conversation worth having with both your doctor and your insurer.
Medicare and the Cardiovascular Loophole
Medicare has historically been prohibited by law from covering medications prescribed specifically for obesity or weight loss.3KFF. A New Use for Wegovy Opens the Door to Medicare Coverage for Millions of People with Obesity This exclusion dates back to a statutory provision that has been in place for decades, and it has left millions of older adults without access to newer anti-obesity medications through their Part D plans.
The FDA’s 2024 approval of Wegovy for cardiovascular risk reduction changed the equation for some Medicare beneficiaries. The SELECT trial, which enrolled over 17,000 adults with established cardiovascular disease and overweight or obesity but without diabetes, found that semaglutide reduced major adverse cardiac events by about 20% compared to placebo over an average exposure of roughly 33 months.4PubMed. Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes5American College of Cardiology. Semaglutide Effects on Cardiovascular Outcomes in People With Overweight or Obesity – SELECT Because the cardiovascular indication is distinct from the weight management indication, Medicare Part D plans can now cover Wegovy when it is prescribed to reduce heart attack, stroke, and cardiovascular death risk in eligible patients. The key requirement is that the prescription is written for the cardiovascular indication, not for weight loss alone.
This does not mean every Medicare beneficiary with obesity can now get Wegovy covered. You generally need documented cardiovascular disease and overweight or obesity, and your Part D plan still decides whether to include the drug on its formulary and at what cost-sharing level. But for millions of Medicare enrollees who meet those criteria, a medication that was completely off-limits is now potentially accessible. If you are on Medicare and have both heart disease and excess weight, it is worth asking your cardiologist or primary care provider whether you qualify under the cardiovascular indication.
Medicaid Coverage by State
Medicaid coverage for anti-obesity medications is a patchwork. As of early 2023, only about one in five state Medicaid programs with public preferred drug lists covered at least one anti-obesity medication, and just 11% had unrestricted coverage of any such drug.6JAMA. State Coverage and Reimbursement of Antiobesity Medications in Medicaid The situation has been shifting as more states reconsider their policies in response to growing demand and the cardiovascular evidence, but progress is uneven. Some states have added coverage with strict prior authorization criteria, while others still exclude the entire drug class.
Researchers have been tracking how state-level Medicaid coverage decisions affect real-world use of GLP-1 medications for obesity, finding significant variation in both who gets the drugs and what they cost the state after manufacturer rebates.7National Bureau of Economic Research. Medicaid Coverage for Obesity Medications: Utilization and Net-of-Rebate Spending If you are on Medicaid and interested in Wegovy, the first step is checking whether your state’s program currently covers it. Your prescriber’s office or a Medicaid customer service representative can tell you the current formulary status and any authorization requirements.
Filling the Prescription
Once you have a prescription and know your coverage situation, the actual ordering process is straightforward but involves a few steps worth knowing about. Wegovy is classified as a specialty medication by many insurers, which means it may need to be filled through a specialty pharmacy rather than your neighborhood drugstore. Your insurer’s benefit documents or the pharmacy itself can tell you whether this applies to your plan. Specialty pharmacies often ship the medication directly to your home in temperature-controlled packaging, since semaglutide pens need to be refrigerated before first use.
Supply shortages have been an ongoing issue with Wegovy since its launch in 2021. Novo Nordisk has periodically limited the availability of certain dose strengths, which can make it difficult to start or stay on the titration schedule. The supply situation has improved over time but has not fully stabilized. If your pharmacy cannot fill a particular dose, your prescriber may be able to adjust the plan or try a different pharmacy. Keeping communication open between your doctor’s office and your pharmacy helps avoid gaps in treatment, which matter because interruptions can mean restarting at a lower dose.
Why Compounded Semaglutide Is Not a Safe Shortcut
The high cost of brand-name Wegovy has driven significant demand for compounded versions of semaglutide, typically offered at a fraction of the price through compounding pharmacies and some telehealth platforms. Compounded semaglutide is not the same product as Wegovy. It is mixed to order by compounding pharmacies and has not undergone the same FDA review for safety, potency, or sterility. The distinction matters more than many people realize.
An analysis of FDA adverse event reports found that compounded GLP-1 medications had higher rates of reported problems compared to the manufactured versions. Compounded products showed roughly three times the reporting rate for abdominal pain, more than six times the rate for suicidality reports, and over three times the rate for gallbladder inflammation. Reports of preparation errors were dramatically elevated, as were reports of contamination and other manufacturing-related issues. The odds of hospitalization associated with adverse events were more than twice as high for compounded products.8PubMed. Safety analysis of compounded GLP-1 receptor agonists: a pharmacovigilance study using the FDA adverse event reporting system Case reports have described serious complications, and the American Diabetes Association has recommended against using compounded GLP-1 medications due to uncertainty about their content, safety, quality, and effectiveness.9Journal of the Endocrine Society. SUN-579 Patient with No Prior History of Diabetes Mellitus Develops Acute Pancreatitis and Diabetic Ketoacidosis on Compounded Semaglutide
The appeal of compounded semaglutide is understandable when brand-name Wegovy costs over $1,300 a month, but the risk profile is genuinely different. You cannot be sure what concentration you are injecting, whether it was stored properly, or whether it contains exactly what the label says. If cost is the barrier, exploring manufacturer savings programs, insurance appeals, or alternative covered medications with your doctor is a safer path than turning to unregulated compounded products.
What Happens When You Stop Taking Wegovy
One of the most important things to understand about Wegovy before you order it is that the weight loss it produces tends to reverse when you stop. In the STEP 1 trial extension, participants who discontinued semaglutide after about 68 weeks regained roughly two-thirds of the weight they had lost by the time another year had passed. The net result was that they still weighed about 5.6% less than when they started, but most of the cardiometabolic improvements seen during active treatment also faded back toward where they had been before.10PubMed Central. Weight regain and cardiometabolic effects after withdrawal of semaglutide: The STEP 1 trial extension
Real-world data paints a somewhat more variable picture. A study tracking patients who stopped semaglutide or tirzepatide in clinical practice found that, on average, weight stayed relatively stable in the first year after discontinuation, but there was considerable individual-level variability: some people regained significantly, others maintained their losses, and some continued losing.11PubMed Central. Obesity Treatments and Weight Changes in Clinical Practice After Discontinuation of Semaglutide or Tirzepatide What made the difference in many cases was whether patients transitioned to another weight-management strategy after stopping. One study of patients who moved from a GLP-1 medication to less expensive generic anti-obesity drugs found that they maintained their weight loss at 18 months and even continued losing, averaging about 25% total weight loss from their initial visit.12PubMed Central. Weight maintenance on cost-effective antiobesity medications after 1 year of GLP-1 receptor agonist therapy: a real-world study
The clinical framing you will hear from obesity medicine specialists is that obesity is a chronic disease requiring ongoing treatment, similar to how blood pressure medications need to be taken continuously to keep working. That framing is supported by the evidence but creates a real tension with the cost and access barriers described above. If you are planning to start Wegovy, it is worth having an honest conversation with your provider about the long-term plan: can you afford it indefinitely, does your insurance coverage seem stable, and what is the fallback strategy if you need to stop?
Cost as the Main Barrier to Staying on Treatment
The connection between cost and discontinuation cannot be overstated. The study of commercially insured semaglutide users found that higher copays, lower household income, and lower education levels were all independently associated with higher rates of stopping the medication.1Wiley Online Library. Titration and discontinuation of semaglutide for weight management in commercially insured US adults Nearly half of all users had discontinued within five months, and this rate barely budged even after the initial supply shortages eased: among patients who started after supply had stabilized, 48% still stopped within five months.
This means the biggest practical consideration when “ordering Wegovy” is not the logistics of getting the prescription filled. It is whether you can sustain the cost month after month for as long as you want the benefits to last. The medication works well while you take it, but the financial commitment is open-ended. Before starting, get the clearest possible picture of your monthly out-of-pocket cost. Ask your insurer for a cost estimate at the maintenance dose, not just the lower starting doses. Check whether manufacturer copay assistance applies to your situation and for how long. And if the number is uncomfortably high, discuss alternatives with your prescriber rather than starting a medication you may have to abandon in a few months.
Navigating Prior Authorization and Denials
Many insurers require prior authorization before they will cover Wegovy, which means your doctor’s office submits documentation proving you meet the plan’s criteria. Common requirements include a BMI at or above the FDA-approved threshold, documentation of previous weight loss attempts such as dietary counseling or structured programs, and sometimes evidence of specific comorbidities. The prior authorization process can take anywhere from a few days to a few weeks, and initial denials are not unusual.
If your prior authorization is denied, you generally have the right to appeal. The most effective appeals include a letter from your prescriber explaining why Wegovy is medically necessary for you, any relevant lab results or clinical notes, and reference to the FDA-approved indications. For patients with established cardiovascular disease, citing the cardiovascular risk reduction indication can sometimes overcome a plan’s blanket exclusion of “weight loss medications,” since the drug is being prescribed for a cardiac purpose. Some advocacy organizations and the prescribing provider’s office can help navigate the appeals process.
It is also worth knowing that insurance formularies change. A plan that does not cover Wegovy this year might add it next year, especially as more evidence accumulates for the cardiovascular benefits and as employers respond to employee demand. Checking back with your insurer at each plan renewal period is a reasonable habit if coverage was previously denied.
Biosimilars and Future Pricing
Semaglutide’s core patents will eventually expire, and several companies are developing biosimilar or generic versions of GLP-1 receptor agonist medications. When biosimilars reach the market, they are expected to cost substantially less than the brand-name product, following the pattern seen with other biologic drugs. However, the timeline remains uncertain, and it could be several years before affordable alternatives are widely available in U.S. pharmacies.
In the meantime, Novo Nordisk has faced increasing public and political pressure over Wegovy’s pricing, particularly given that the same drug is available at far lower prices in other countries. Some legislative proposals have targeted Medicare’s statutory exclusion of weight loss drugs, and others have focused on price negotiation. Whether any of these efforts translate into lower costs for patients in the near term is unclear, but the political and market dynamics around GLP-1 medications are shifting faster than almost any other drug class. If you are weighing whether to start Wegovy now or wait, the honest answer is that costs are unlikely to drop dramatically in the next year or two, but the coverage landscape five years from now will probably look quite different.